" class="no-js "lang="en-US"> Rinri Therapeutics - Medtech Alert
Tuesday, August 19, 2025

Breaking News

Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Astellas and Cullgen Enter into Strategic Collaboration and Option Agreement to Advance Innovative Targeted Protein Degraders Auxilius Pharma Raises Seed Funding of $1 Million and Commences its Clinical Program Captivate Bio and EverCell Bio partner on Human Cell Modeling Services for Cell and Gene Therapy Markets Applied StemCell Partners with CIRM to Provide Clinical-Grade iPSCs and Access to Its Proprietary Gene Editing Technologies Alentis Therapeutics Receives IND Clearance from FDA for ALE.C04 for the Treatment of CLDN1+ Tumors
Rinri Therapeutics | Pharmtech Focus

Rinri Therapeutics

About Rinri Therapeutics

Rinri Therapeutics

Founded in 2018, Rinri Therapeutics Ltd. is a therapeutic discovery and development company working in the field of hearing loss supported by Boehringer Ingelheim and UCB Venture Funds, BioCity and The University of Sheffield.

Rinri Therapeutics has been founded on pioneering research into auditory stem cells led by Professor Marcelo Rivolta at the University of Sheffield.

The Company has a team of experienced management, strong academic pedigree and excellent potential for clinical development.

What is the origin of the name?
‘Rinri’ means ear in Quechua, a language spoken by some of the original people of South America.

Related Story

Fundraising

 Rinri Therapeutics Raises £10 million from Existing Investors and UK Future Fund to Advance its Novel Stem Cell Therapy to Restore Hearing Loss | Pharmtech Focus

Rinri Therapeutics Raises £10 million from Existing Investors and UK Future Fund to Advance its Novel Stem Cell Therapy to Restore Hearing Loss

April 20 2021

Rinri Therapeutics, a biotechnology company developing a novel stem cell therapy to restore hearing, today […]